Clinical trial
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in…
NCT00091026 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00091026 |
|---|---|
| Title | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer |
| Official title | A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination With Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, gemcitabine hydrochloride, bevacizumab, erlotinib hydrochloride |
| Enrollment | 143 |
| Start date | Jul 1, 2004 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Sep 8, 2004 |
| Last update posted | May 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: